Journal of Jilin University(Medicine Edition) ›› 2024, Vol. 50 ›› Issue (1): 168-177.doi: 10.13481/j.1671-587X.20240121
• Research in clinical medicine • Previous Articles Next Articles
Xiaoyan WANG1,2,Hao ZHANG2,3,Zehao GUO2,3,Jun CAO2,3,Zhijing MO2,3(
)
Received:2023-03-28
Online:2024-01-28
Published:2024-01-31
Contact:
Zhijing MO
E-mail:mozhijing@glmc.edu.cn
CLC Number:
Xiaoyan WANG,Hao ZHANG,Zehao GUO,Jun CAO,Zhijing MO. Screening of UBE2S interacting protein and construction of prognostic model in hepatocellular carcinoma[J].Journal of Jilin University(Medicine Edition), 2024, 50(1): 168-177.
Tab.1
Informations of top 20 ranked proteins by score analyzed by LC-MS"
| PF number | Accession | Score | Mass | Match | Sequence | emPAI | Protein |
|---|---|---|---|---|---|---|---|
| 3 | P08670 | 873 | 53 676 | 24 | 16 | 3.17 | VIM |
| 6 | P62736 | 588 | 42 381 | 26 | 13 | 3.49 | ACTA2 |
| 9 | P13645 | 509 | 59 020 | 11 | 8 | 0.82 | KRT10 |
| 11 | Q92614 | 385 | 234 168 | 6 | 5 | 0.09 | MYO18A |
| 13 | P11142 | 330 | 71 082 | 6 | 5 | 0.31 | HSPA8 |
| 14 | P06733 | 314 | 47 481 | 6 | 5 | 0.50 | ENO1 |
| 15 | P35527 | 311 | 62 255 | 5 | 5 | 0.29 | KRT9 |
| 16 | P35908 | 294 | 65 678 | 7 | 6 | 0.41 | KRT2 |
| 17 | P02533 | 282 | 51 872 | 6 | 5 | 0.45 | KRT14 |
| 18 | P08779 | 277 | 51 578 | 6 | 5 | 0.45 | KRT16 |
| 20 | P25705 | 245 | 59 828 | 3 | 3 | 0.17 | ATP5F1A |
| 22 | P11021 | 231 | 72 402 | 5 | 5 | 0.25 | HSPA5 |
| 24 | Q9BQE3 | 212 | 50 548 | 5 | 4 | 0.37 | TUBA1C |
| 25 | P06396 | 195 | 86 043 | 6 | 4 | 0.25 | GSN |
| 26 | P23396 | 190 | 26 842 | 4 | 4 | 0.60 | RPS3 |
| 27 | P07437 | 175 | 50 095 | 4 | 4 | 0.29 | TUBB |
| 30 | A0A075B6S2 | 133 | 13 249 | 4 | 2 | 0.58 | IGKV2D-29 |
| 31 | P01023 | 125 | 164 613 | 2 | 2 | 0.04 | A2M |
| 32 | P52272 | 122 | 77 749 | 3 | 2 | 0.13 | HNRNPM |
| 33 | P13929 | 117 | 47 299 | 2 | 2 | 0.14 | ENO3 |
Tab.2
Informations of top 20 ranked proteins in Venn diagram"
| Gene name | Gene ID | Gene biotype | HR | 95% CI | PCox |
|---|---|---|---|---|---|
| CCT3 | ENSG00000163468 | Protein coding | 2.087 | 1.459-2.985 | 5.63687E-05 |
| TUBA1C | ENSG00000167553 | Protein coding | 2.040 | 1.433-2.904 | 7.63003E-05 |
| ARPC4 | ENSG00000241553 | Protein coding | 2.048 | 1.433-2.928 | 8.44439E-05 |
| ENO1 | ENSG00000074800 | Protein coding | 1.982 | 1.390-2.826 | 0.000 156 723 |
| HNRNPH1 | ENSG00000169045 | Protein coding | 1.950 | 1.366-2.784 | 0.000 236 773 |
| PRDX1 | ENSG00000117450 | Protein coding | 1.899 | 1.338-2.696 | 0.000 333 502 |
| H2AZ1 | ENSG00000164032 | Protein coding | 1.902 | 1.335-2.710 | 0.000 369 261 |
| IDH3B | ENSG00000101365 | Protein coding | 1.840 | 1.294-2.615 | 0.000 684 482 |
| RAB6A | ENSG00000175582 | Protein coding | 1.831 | 1.287-2.605 | 0.000 769 835 |
| SLC2A1 | ENSG00000117394 | Protein coding | 1.813 | 1.275-2.577 | 0.000 926 358 |
| PKM | ENSG00000067225 | Protein coding | 1.807 | 1.271-2.568 | 0.000 975 417 |
| EIF2S1 | ENSG00000134001 | Protein coding | 1.774 | 1.246-2.524 | 0.001 459 454 |
| SLC25A3 | ENSG00000075415 | Protein coding | 1.758 | 1.239-2.495 | 0.001 574 133 |
| YWHAZ | ENSG00000164924 | Protein coding | 1.758 | 1.238-2.496 | 0.001 614 956 |
| CAPZA2 | ENSG00000198898 | Protein coding | 1.740 | 1.221-2.477 | 0.002 150 215 |
| RPL18 | ENSG00000063177 | Protein coding | 1.723 | 1.214-2.447 | 0.002 339 329 |
| CALM1 | ENSG00000198668 | Protein coding | 1.709 | 1.200-2.432 | 0.002 938 229 |
| AKR1B10 | ENSG00000198074 | Protein coding | 1.711 | 1.198-2.444 | 0.003 143 354 |
| WTAP | ENSG00000146457 | Protein coding | 1.704 | 1.196-2.427 | 0.003 170 283 |
| ACTR3 | ENSG00000115091 | Protein coding | 1.670 | 1.177-2.369 | 0.004 042 542 |
| 1 | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. |
| 2 | CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791. |
| 3 | KIRKIN V, DIKIC I. Ubiquitin networks in cancer[J]. Curr Opin Genet Dev, 2011, 21(1): 21-28. |
| 4 | LI Z Y, WANG Y, LI Y D, et al. Ube2s stabilizes β-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development[J]. Cell Death Dis, 2018, 9(5): 456. |
| 5 | TANG H, FANG T, JI M, et al. UBE2S exerts oncogenic activities in urinary bladder cancer by ubiquitinating TSC1[J]. Biochem Biophys Res Commun, 2021, 578: 7-14. |
| 6 | HU L, CHENG X B, BINDER Z, et al. Molecular and clinical characterization of UBE2S in glioma as a biomarker for poor prognosis and resistance to chemo-radiotherapy[J]. Front Oncol, 2021, 11: 640910. |
| 7 | ZHANG M J, LIU Y, YIN Y, et al. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis[J]. Mol Med, 2022, 28(1): 62. |
| 8 | HU W J, LI M, CHEN Y G, et al. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway[J]. J Ovarian Res, 2021, 14(1): 121. |
| 9 | LIN T H, HSU W H, TSAI P H, et al. Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling[J]. Food Funct, 2017, 8(4): 1558-1568. |
| 10 | LIU Z, XU L J. UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells[J]. BMB Rep, 2018, 51(12): 642-647. |
| 11 | HO J Y, LU H Y, CHENG H H, et al. UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells[J]. Cell Oncol (Dordr), 2021, 44(6): 1325-1338. |
| 12 | QIN Y N, DU J, FAN C F. Ube2S regulates Wnt/β-catenin signaling and promotes the progression of non-small cell lung cancer[J].Int J Med Sci,2020,17(2): 274-279. |
| 13 | GUO Y J, CHEN X Y, ZHANG XW, et al. UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb [J]. Front Oncol, 2023, 13: 992233. |
| 14 | PENG S M, CHEN X, HUANG C Y, et al. UBE2S as a novel ubiquitinated regulator of p16 and β-catenin to promote bone metastasis of prostate cancer[J]. Int J Biol Sci, 2022, 18(8): 3528-3543. |
| 15 | PAN Y H, YANG M, LIU L P, et al. UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2018, 503(2): 895-902. |
| 16 | ZHANG R Y, LIU Z K, WEI D, et al. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development[J]. Signal Transduct Target Ther, 2021, 6(1): 64. |
| 17 | GUI L, ZHANG S C, XU Y Z, et al. UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma[J]. Cell Death Discov, 2021, 7(1): 357. |
| 18 | MA Y L, LI K Z, LI S J, et al. Prognostic value of ubiquitin-conjugating enzyme E2 S overexpression in hepatocellular carcinoma[J]. Int J Biol Macromol, 2018, 119: 225-231. |
| 19 | GOEMAN J J. L1 penalized estimation in the Cox proportional hazards model[J]. Biom J, 2010, 52(1): 70-84. |
| 20 | COMBS J A, DENICOLA G M. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival[J]. Cancers,2019,11(5): 678. |
| 21 | ANGELI J P F, SCHNEIDER M, PRONETH B,et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J].Nat Cell Biol,2014, 16(12): 1180-1191. |
| 22 | YANG W S, SRIRAMARATNAM R, WELSCH M E,et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1/2): 317-331. |
| 23 | JIANG X J, STOCKWELL B R, CONRAD M. Ferroptosis: mechanisms, biology and role in disease[J].Nat Rev Mol Cell Biol,2021,22(4):266-282. |
| 24 | MATSCHKE V, THEISS C, MATSCHKE J. Oxidative stress: the lowest common denominator of multiple diseases[J]. Neural Regen Res, 2019, 14(2): 238-241. |
| 25 | WANG J, CHEN W, WEI W W, et al. Oncogene TUBA1C promotes migration and proliferation in hepatocellular carcinoma and predicts a poor prognosis[J]. Oncotarget, 2017, 8(56): 96215-96224. |
| 26 | JIANG K Q, DONG C Y, YIN Z L, et al. Exosome-derived ENO1 regulates integrin α6β4 expression and promotes hepatocellular carcinoma growth and metastasis[J]. Cell Death Dis, 2020, 11(11): 972. |
| 27 | XU H, DONG X Y, CHEN Y M, et al. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma[J]. Clin Chem Lab Med, 2018, 56(3): 479-484. |
| 28 | CHEN Y H, PENG C H, CHEN J R, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1[J]. Mol Cancer, 2019, 18(1): 127. |
| 29 | YANG C X, SHAO Y D, WANG X J, et al. The effect of the histone chaperones HSPA8 and DEK on tumor immunity in hepatocellular carcinoma[J]. Int J Mol Sci, 2023, 24(3): 2653. |
| 30 | DUAN F F, WU H, JIA D W, et al. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis[J]. J Hepatol, 2018, 68(6): 1191-1202. |
| 31 | HUANG S L, DONG C R, LI D, et al. ARPC2: a pan-cancer prognostic and immunological biomarker that promotes hepatocellular carcinoma cell proliferation and invasion[J]. Front Cell Dev Biol, 2022, 10: 896080. |
| [1] | Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780. |
| [2] | Xiaohui LIANG,Wenna LIU,Jianbo ZHAO. Bioinformatic analysis on PAQR3 expression in hepatocellular carcinoma and its correlations with T lymphocyte infiltration, immune checkpoint genes, and patient survival [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 781-790. |
| [3] | Xiqian ZHANG,Zhibo DANG,Yunan DU,Pei WU,Hang XIE,Gaofeng TAN. Inhibitory effect of Chaiqi Yigan formula on malignant biological behaviors of liver cancer HepG2 cells by regulating macrophage polarization [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 398-409. |
| [4] | Jiaxin WANG,Junwen MAO,Xuan ZHANG. Expression of natural autoantibodies against apoptosis inhibitory genes in plasma of patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 228-235. |
| [5] | Limei WEN,Yali GUO,Wenmei MA,Taotao XUE,Ruoyu GENG,Chong MA,Xinhong ZHANG,Jianhua YANG. Bioinformatic analysis of TCGA database based on INPP4B gene expression in hepatocellular carcinoma and its experimental validation [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1618-1629. |
| [6] | Han LIN,Qiuyan YANG,Jieyue ZHONG,Bolun CHEN,Wangxia TONG. Improvement effect of cordycepin on ferroptosis in HepG2 cells induced by RSL3 and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 576-589. |
| [7] | Xiaoyan WANG,Xuelian LI,Bin LIANG,Wenfei TIAN,Hailin MA,Zhijing MO. Analysis on relationship between CALU and prognosis of hepatocellular carcinoma patients and its mechanism based on transcriptome and single cell sequencing data [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 447-459. |
| [8] | Yongjing YANG,Tianyang KE,Shixin LIU,Xue WANG,Dequan XU,Tingting LIU,Ling ZHAO. Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1009-1015. |
| [9] | Jinlian LI,Lanzhen HUANG,Xishi HUANG,Kangzhi LI,Jiali JIANG,Miaomiao ZHANG,Qunying WU. Bioinformatics analysis on key genes related to prognosis, diagnosis, and immune cell infiltration of hepatocellular carcinoma and their potential therapeutic drugs [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1062-1075. |
| [10] | Xiaopeng YU,Renyi YANG,Zuomei HE,Puhua ZENG. Establishment and validation of nomogram of cancer specific survival of patients with hepatocellular carcinoma with negative alpha fetoprotein based on SEER Database [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 188-197. |
| [11] | Yong DONG,Lingyao XU,Jing HUA,Han LIANG,Dongya LIU,Junbo ZHAO,Zhenglu SUN,Cheng CHENG,Shutang WEI. Effect of macrophage exosomal lncRNA HULC on migration, invasion,and metastasis of hepatocellular carcinoma cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1217-1226. |
| [12] | Wenjun DENG,Liantao HU,Binnan ZHAO,Xinyu DONG,Xuebin LI,Jie LI,Xinyan YANG,Xiaoli GUO,Yue LI,Yikun QU,Weiqun WANG. Effect of CXC chemokine ligand 10 on proliferation and migration of hepatocellular carcinoma SMMC-7721 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1227-1233. |
| [13] | Yaqi XU,Yanyu WANG,Wenjing ZHANG,Mei HAN,Huaxia MU,Xi YANG,Weixiao BU,Zikun TAO,Yujia KONG,Fuyan SHI,Suzhen WANG. Bioinformatics analysis on screening of key genes of hepatitis B virus-related hepatocellular carcinoma and its relationship with prognosis [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1243-1252. |
| [14] | Yuanyuan LIANG,Song ZHAO,Jing HU,Ni AN,Yanlu WEI,Rongjian SU. Effect of motesanib combined with EZH2 inhibitor GSK126 on proliferation and apoptosis of liver cancer Huh7 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(4): 896-904. |
| [15] | Junyi JIN,Mu LI,Yaoyuan HU,Yihui WANG. Targeting relationship between miR-150-5p and NCAPG and its inhibitory effect on hepatocellular carcinoma Huh7 cells [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 122-130. |